MX2010002264A - Composiciones y métodos para utilizar péptidos proislet y sus analogos. - Google Patents

Composiciones y métodos para utilizar péptidos proislet y sus analogos.

Info

Publication number
MX2010002264A
MX2010002264A MX2010002264A MX2010002264A MX2010002264A MX 2010002264 A MX2010002264 A MX 2010002264A MX 2010002264 A MX2010002264 A MX 2010002264A MX 2010002264 A MX2010002264 A MX 2010002264A MX 2010002264 A MX2010002264 A MX 2010002264A
Authority
MX
Mexico
Prior art keywords
methods
analogs
compositions
proislet peptides
proislet
Prior art date
Application number
MX2010002264A
Other languages
English (en)
Spanish (es)
Inventor
Victor M Garsky
Claresa S Levetan
Original Assignee
Curedm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curedm Inc filed Critical Curedm Inc
Publication of MX2010002264A publication Critical patent/MX2010002264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
MX2010002264A 2007-08-30 2008-08-29 Composiciones y métodos para utilizar péptidos proislet y sus analogos. MX2010002264A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96901907P 2007-08-30 2007-08-30
US97952607P 2007-10-12 2007-10-12
US99196407P 2007-12-03 2007-12-03
US3147908P 2008-02-26 2008-02-26
PCT/US2008/074868 WO2009029847A1 (en) 2007-08-30 2008-08-29 Compositions and methods of using proislet peptides and analogs thereof

Publications (1)

Publication Number Publication Date
MX2010002264A true MX2010002264A (es) 2010-08-02

Family

ID=40084133

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010002264A MX2010002264A (es) 2007-08-30 2008-08-29 Composiciones y métodos para utilizar péptidos proislet y sus analogos.
MX2013001304A MX337147B (es) 2007-08-30 2008-08-29 Composiciones y metodos para utilizar peptidos proislet y sus analogos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013001304A MX337147B (es) 2007-08-30 2008-08-29 Composiciones y metodos para utilizar peptidos proislet y sus analogos.

Country Status (25)

Country Link
US (2) US8816047B2 (enExample)
EP (3) EP2570431A3 (enExample)
JP (2) JP2010538017A (enExample)
KR (1) KR20100080519A (enExample)
CN (1) CN101896499B (enExample)
AU (1) AU2008292913B2 (enExample)
BR (1) BRPI0815308A2 (enExample)
CA (1) CA2698100C (enExample)
CO (1) CO6270235A2 (enExample)
CY (1) CY1116169T1 (enExample)
DK (1) DK2193142T3 (enExample)
EA (1) EA201000399A1 (enExample)
ES (1) ES2534434T3 (enExample)
HR (1) HRP20150330T1 (enExample)
IL (2) IL233024A (enExample)
MA (1) MA31822B1 (enExample)
MX (2) MX2010002264A (enExample)
MY (1) MY165889A (enExample)
NZ (3) NZ583679A (enExample)
PL (1) PL2193142T3 (enExample)
PT (1) PT2193142E (enExample)
SG (1) SG185940A1 (enExample)
SI (1) SI2193142T1 (enExample)
WO (1) WO2009029847A1 (enExample)
ZA (1) ZA201001798B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1883417A2 (en) 2005-05-25 2008-02-06 Curedm Inc. Peptides, derivatives and analogs thereof, and methods of using same
ES2534434T3 (es) * 2007-08-30 2015-04-22 Curedm Group Holdings, Llc Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
EP2679270B1 (en) * 2011-02-24 2016-11-09 Hisamitsu Pharmaceutical Co., Inc. Glp-1 analogue composition for microneedle devices
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
RU2480234C1 (ru) * 2012-03-01 2013-04-27 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" Способ профилактики и лечения нарушений углеводного и липидного обмена при метаболическом синдроме и энцефалопатии, применение тетрапептида и фармацевтическая композиция для профилактики и лечения таких нарушений
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
EP2900691A4 (en) * 2012-09-27 2016-04-20 Claresa Levetan GENERATION OF NEW CELLS BETA OF PANCREAS
WO2014052625A1 (en) * 2012-09-27 2014-04-03 Levetan Claresa Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
CN104045702A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
WO2014139182A1 (en) * 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN104045701A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104650212A (zh) * 2013-03-15 2015-05-27 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
CN104045698B (zh) * 2013-03-15 2019-04-16 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045703B (zh) * 2013-03-15 2021-04-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045700A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104592380A (zh) * 2013-03-15 2015-05-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
CN104045699A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
US9321812B2 (en) * 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2015158241A1 (en) * 2014-04-18 2015-10-22 National Institute Of Biological Sciences, Beijing Reg3 therapeutics
TWI668010B (zh) * 2014-05-07 2019-08-11 丹麥商諾佛 儂迪克股份有限公司 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN105727262B (zh) * 2014-12-08 2020-08-25 华东师范大学 胰再生源蛋白在制备促进过度炎症伤口愈合的药物中的应用
CN105732793A (zh) * 2014-12-08 2016-07-06 华东师范大学 一种胰再生源蛋白衍生物及其应用
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US11020462B2 (en) 2015-08-28 2021-06-01 Serpin Pharma Methods for treatment of diseases
CN109195983B (zh) * 2016-03-10 2022-05-17 深圳君圣泰生物技术有限公司 胰岛新生多肽和类似物的缀合物及其方法
US10772929B2 (en) * 2017-05-11 2020-09-15 Shenzhen Hightide Biopharmaceutical, Ltd. Use of peptide compounds in treating acute pancreatitis
KR101995768B1 (ko) 2019-03-13 2019-07-03 (주)엔솔바이오사이언스 신규 펩타이드 및 그 용도
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2020252260A1 (en) * 2019-06-13 2020-12-17 Regeneron Pharmaceuticals, Inc. Methods for removing undesired components during multistage chromatographic processes
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
CN117442585B (zh) * 2023-12-25 2024-03-19 北京爱思益普生物科技股份有限公司 一种靶向胰腺癌的雷公藤红素递送体及其制备方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5261752A (en) * 1991-09-12 1993-11-16 Nsk Ltd. Bearing having passive pulser ring
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
PL184145B1 (pl) 1994-12-21 2002-09-30 Yeda Res & Dev Analogi peptydu p277, środek diagnostyczny do diagnozowania IDDM, sposób wykrywania IDDM, środek farmaceutyczny do leczenia lub zapobiegania IDDM
DE69638315D1 (de) 1995-02-22 2011-02-17 Eastern Virginia Med School Ingap-protein und dessen beteiligung an der neogenese pankreatischer inselzellen
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE19735587B4 (de) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20040132644A1 (en) 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
EP1477496A4 (en) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG BINDING PTH OR PEG BINDING PTH DERIVATIVE
US7166439B2 (en) * 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies
AU2003241388A1 (en) * 2002-05-09 2003-11-11 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
WO2003105897A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
US6946151B2 (en) 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
BRPI0406800B8 (pt) * 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
EP3000886A1 (en) 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2005035761A1 (en) * 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
KR20070094909A (ko) * 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP1883417A2 (en) * 2005-05-25 2008-02-06 Curedm Inc. Peptides, derivatives and analogs thereof, and methods of using same
EP1907857A4 (en) * 2005-05-26 2009-08-05 Univ Johns Hopkins BIOMARKER FOR BREAST CANCER
CN100429227C (zh) * 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin4多肽片段
WO2007102526A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
WO2008064306A2 (en) * 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
ES2534434T3 (es) 2007-08-30 2015-04-22 Curedm Group Holdings, Llc Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
US20110082080A1 (en) * 2007-10-12 2011-04-07 Curedm Group Holdings, Llc Compositions and methods of using the human proislet peptide receptor

Also Published As

Publication number Publication date
IL204183A (en) 2017-06-29
CN101896499A (zh) 2010-11-24
JP2010538017A (ja) 2010-12-09
MA31822B1 (fr) 2010-11-01
EP2570431A2 (en) 2013-03-20
JP2014028825A (ja) 2014-02-13
CA2698100A1 (en) 2009-03-05
EA201000399A1 (ru) 2011-02-28
ZA201001798B (en) 2015-04-29
EP2559700A2 (en) 2013-02-20
SI2193142T1 (sl) 2015-05-29
WO2009029847A8 (en) 2009-11-05
BRPI0815308A2 (pt) 2016-07-19
AU2008292913B2 (en) 2014-06-05
PL2193142T3 (pl) 2015-06-30
CY1116169T1 (el) 2017-02-08
EP2193142B1 (en) 2015-01-07
SG185940A1 (en) 2012-12-28
MY165889A (en) 2018-05-18
ES2534434T3 (es) 2015-04-22
EP2570431A3 (en) 2013-05-01
EP2559700A3 (en) 2013-03-13
HK1144823A1 (en) 2011-03-11
DK2193142T3 (da) 2015-04-20
US8816047B2 (en) 2014-08-26
NZ583679A (en) 2012-05-25
MX337147B (es) 2016-02-15
IL233024A0 (en) 2014-07-31
US20110171178A1 (en) 2011-07-14
PT2193142E (pt) 2015-04-22
IL233024A (en) 2016-07-31
CA2698100C (en) 2017-06-06
CN101896499B (zh) 2014-02-12
KR20100080519A (ko) 2010-07-08
US20150018272A1 (en) 2015-01-15
EP2193142A1 (en) 2010-06-09
JP5960661B2 (ja) 2016-08-02
WO2009029847A1 (en) 2009-03-05
NZ599755A (en) 2013-08-30
AU2008292913A1 (en) 2009-03-05
NZ599756A (en) 2013-09-27
HRP20150330T1 (hr) 2015-06-19
CO6270235A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
MY165889A (en) Compositions and methods of using proislet peptides and analogs thereof
TW200635610A (en) Injectable non-aqueous suspension
MX2010008138A (es) Forma de dosis farmaceutica.
EA201170703A1 (ru) Производные адамантилбензамида
TW200700086A (en) Injectable non-aqueous suspension
GEP20125565B (en) Lactam compounds and their pharmaceutical use
PH12012502121A1 (en) Peptide conjugates of glp-1 receptor agonists and gastrin and their use
MY157365A (en) Chemical compounds and uses
SG161311A1 (en) Novel use of spiegelmers
GEP20146056B (en) Acylated glucagon analogues
WO2007022518A3 (en) New uses of glucoregulatory proteins
IN2012DN01233A (enExample)
MY158438A (en) Antibodies against human angiopoietin 2
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
TW200714277A (en) Methods and compositions for altering cell fuction
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
EA028951B9 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MX338357B (es) Compuestos estables de la hormona de crecimiento.
EA201201623A1 (ru) Лечение диабета 2 типа
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights